“Will the Biotech Bubble Burst?”
Given the continued upswing of biotech valuation and stocks, many debate whether or not this “biotech bubble” will eventually burst. Join us for an engaging panel featuring three industry experts, as they share their points of view on the future of biotechnology. This event is part of Boston Idea Week.
Steven Ertel, Chief Business Officer, Acceleron Pharma
Steven Ertel joined Acceleron in January 2006 and is Senior Vice President and Chief Business Officer. Ertel established Acceleron’s business development function and currently leads business development, commercial strategy, and program management functions. He has over 20 years of experience in the biotechnology industry, including program management for preclinical and clinical stage programs, commercial strategy for clinical state programs, market launch of a novel biologic agent, and business development.
Jonathan Gertler, MD, Managing Partner & CEO, Back Bay Life Science Advisors
Dr. Jonathan Gertler is managing partner and CEO at Back Bay Life Science Advisors. He has been advising companies in the life sciences since the 1990s. Dr. Gertler provides counsel and analysis on franchise and therapeutic-area strategies, and corporate and business development activities. He also advises clients on planning and execution of value-creating transactions across the spectrum of size and stage in the life sciences and medtech. His practice encompasses North American and European public and private commercial-stage and R&D-stage companies from mid to large cap; venture-backed companies; and investment firms focused on the life sciences.
Kiran Reddy, MD, Associate Partner, Third Rock Ventures
Kiran Reddy joined Third Rock Ventures in 2013. As an Associate Partner, Kiran supports and manages various portfolio companies in addition to focusing on new company formation and due diligence. He was actively involved in the building and launch of Foundation Medicine and SAGE Therapeutics, and has been a member of the Partner Development Team.